Pro-Dex Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $77.5M+16.5% YoYTTM through 31 Mar 2026
Net Income $13.7M+52.2% YoYTTM through 31 Mar 2026
Free Cash Flow $6.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 31.0% |
| EBITDA Margin | 18.5% |
| Operating Margin | 15.6% |
| Net Margin | 17.6% |
Returns
26.6%ROE
16.0%ROA
24.0%ROIC
Balance Sheet Health
Debt / Equity0.41x
Current Ratio4.10x
Net Debt$8.5M
Cash & Equivalents$8.2M
Quality Metrics
Altman Z-Score8.34
Piotroski F-Score7 / 9
FCF Margin8.7%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2026: $77.5M
Diluted EPS$4.12TTMFY2026: $4.12
Dividend
No dividend
Capital Allocation
R&D Spend$3.3M
Capex Intensity0.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Medical Devices | View detailsContract extension with largest customer through December 2028 provides stability and minimum purchase volumes for 2026 and 2027. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.